Autoantibodies against the Ca2+-binding protein recoverin in blood sera of patients with various oncological diseases

Savchenko,Marina  S.; Goncharskaia,Maria  A.; Skorikova,Elena  E.; Eichmüller,Stefan  B.; Kushlinsky,Nikolay  E.; Bazhin,Alexandr  V.; Philippov,Pavel  P.

doi:10.3892/ol.2011.464

Autoantibodies against the Ca2+-binding protein recoverin in blood sera of patients with various oncological diseases

Authors:
- Marina S. Savchenko
- Maria A. Goncharskaia
- Elena E. Skorikova
- Stefan B. Eichmüller
- Nikolay E. Kushlinsky
- Alexandr V. Bazhin
- Pavel P. Philippov
View Affiliations

Affiliations: Department of Cell Signalling, A.N. Belozersky Institute of Physico-Chemical Biology, M.V. Lomonosov Moscow State University, 119991 Moscow, Russia, Institute of Carcinogenesis, N.N. Blokhin Russian Oncological Scientific Centre, Russian Academy of Medical Sciences, 115478 Moscow, Russia, German Cancer Research Center (DKFZ), Skin Cancer Unit, University Heidelberg, INF 350, D-69120 Heidelberg, Germany, Institute of Clinical Oncology, N.N. Blokhin Russian Oncological Scientific Centre, Russian Academy of Medical Sciences, 115478 Moscow, Russia, Department of Surgery, University Heidelberg, INF 350, D-69120 Heidelberg, Germany
Published online on: October 31, 2011 https://doi.org/10.3892/ol.2011.464
Pages: 377-382

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In cancer, the retinal Ca2+-binding protein recoverin is a paraneoplastic antigen, the aberrant expression of which is capable of triggering the appearance of specific autoantibodies in the serum of patients with malignant tumors and the subsequent development of a paraneoplastic syndrome, cancer-associated retinopathy (CAR). The frequency of serum autoantibodies against recoverin (AAR), earlier determined at a rate of 15-20% in lung cancer, is much higher than the frequency of CAR syndrome, which is approximately 1%. In the present study, we estimated for the first time the frequencies of serum AAR in patients with various types of malignancies other than lung cancer. Patient biospecimens were collected to analyze for the presence of AAR. Additionally, various cell lines were cultivated and analyses were performed using Western blotting and RT-PCR. Results showed that in all cases tested, the AAR frequencies did not exceed 10%. Five AAR-positive patients with various types of cancer were available for ophthalmological investigation and only one of these patients had CAR syndrome. This result is consistent with the conclusion made in our previous studies of lung cancer that serum AAR do not necessarily trigger the development of CAR syndrome.

View Figures

View References

1	Adamus G: The role of recoverin in autoimmunity. Neuronal Calcium Sensor Proteins. Philippov P and Koch KW: Nova Science Publishers, Inc.; New York, NY: pp. 181–199. 2006
2	Dizhur AM, Nekrasova EN and Filippov PP: New 26 kDa protein specific for photoreceptor cells, capable of binding with immobilized delipidized rhodopsin. Biokhimiya. 56:225–229. 1991.PubMed/NCBI
3	Dizhoor AM, Ray S, Kumar S, et al: Recoverin: a calcium sensitive activator of retinal rod guanylate cyclase. Science. 251:915–918. 1991. View Article : Google Scholar : PubMed/NCBI
4	Philippov PP, Senin II and Koch KW: Recoverin: a calcium-dependent regulator of the visual transduction. Neuronal Calcium Sensor Proteins. Philippov P and Koch KW: Nova Science Publishers, Inc.; New York, NY: pp. 139–151. 2006
5	Eichmüller SB and Bazhin AV: Onconeural versus paraneoplastic antigens. Cur Med Chem. 14:2489–2494. 2007.
6	Polans AS, Buczylko J, Crabb J and Palczewski K: A photoreceptor calcium binding protein is recognized by autoantibodies obtained from patients with cancer-associated retinopathy. J Cell Biol. 112:981–989. 1991. View Article : Google Scholar
7	Polans AS, Witkowska D, Haley TL, et al: Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA. 92:9176–9180. 1995. View Article : Google Scholar : PubMed/NCBI
8	Bazhin AV, Shifrina ON, Savchenko MS, et al: Low titer autoantibodies against recoverin in sera of patients with small cell lung cancer but without a loss of vision. Lung Cancer. 34:99–104. 2001. View Article : Google Scholar : PubMed/NCBI
9	Savchenko MS, Bazhin AV, Shifrina ON, et al: Antirecoverin autoantibodies in the patient with non-small lung cancer but without cancer-associated retinopathy. Lung Cancer. 41:363–367. 2003. View Article : Google Scholar : PubMed/NCBI
10	Bazhin AV, Savchenko MS, Shifrina ON, et al: Recoverin as a paraneoplastic antigen in lung cancer: the occurrence of anti-recoverin autoantibodies in sera and recoverin in tumors. Lung Cancer. 44:193–198. 2004. View Article : Google Scholar : PubMed/NCBI
11	Bazhin AV, De Smet C, Golovastova MO, et al: Aberrant demethylation of the recoverin gene is involved in the aberrant expression of recoverin in cancer cells. Exp Dermatol. 19:1023–1025. 2011. View Article : Google Scholar : PubMed/NCBI
12	Bazhin AV, Shifrina ON, Savchenko MS, et al: Application of ELISA and immunoblotting methods for detection of anti-recoverin autoantibodies in sera of small-cell lung carcinoma patients. Pulmonology. 13:62–65. 2003.
13	Senin II, Zargarov AA, Alekseev AM, et al: N-Myristoylation of recoverin enhances its efficiency as an inhibitor of rhodopsin kinase. FEBS Lett. 376:87–90. 1995. View Article : Google Scholar : PubMed/NCBI
14	Maeda A, Ohguro H, Maeda T, et al: Aberrant expression of photoreceptor-specific calcium-binding protein (recoverin) in cancer cell lines. Cancer Res. 60:1914–1920. 2000.PubMed/NCBI
15	Bazhin AV, Schadendorf D, Willner N, et al: Photoreceptor proteins as cancer-retina antigens. Int J Cancer. 120:1268–1276. 2007. View Article : Google Scholar : PubMed/NCBI
16	Graus F, Cordon-Cardo C and Posner JB: Neuronal antinuclear antibody in sensory neuropathy from lung cancer. Neurology. 35:538–543. 1985. View Article : Google Scholar : PubMed/NCBI
17	Hersh B, Dalmau J, Dangond F, et al: Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody. Neurology. 44:1754–1755. 1994. View Article : Google Scholar : PubMed/NCBI
18	Dalmau J, Furneaux HM, Gralla RJ, et al: Detection of anti-Hu antibody in the serum of patients with small cell lung cancer – a quantitative western blot analysis. Ann Neurol. 27:544–552. 1990.
19	Drlicek M, Bianchi G, Bogliun G, et al: Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol. 244:85–89. 1997. View Article : Google Scholar : PubMed/NCBI
20	Bazhin AV, Dalke C, Willner N, et al: Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathy. Int J Cancer. 124:140–149. 2009. View Article : Google Scholar : PubMed/NCBI
21	Matsuo S, Ohguro H, Ohguro I and Nakazawa M: Clinico-pathological roles of aberrantly expressed recoverin in malignant tumor cells. Ophthalmol Res. 43:139–144. 2010. View Article : Google Scholar : PubMed/NCBI
22	Voltz R, Gultekin SH, Rosenfeld MR, et al: A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Eng J Med. 340:1788–1795. 1999. View Article : Google Scholar : PubMed/NCBI